Evidence map›Paper›PMID 39030931›Full record

ArticleJournal of pharmacy practice2025

Development of a Medication-Use Evaluation Template for Andexanet Alfa in the Reversal of Anticoagulation With Factor Xa Inhibitors.

Toni Fera, Allison Burnett, Jessica Grandoni, Mary R Moore, Barbara B Nussbaum, Charles V Pollack, Anne E Rose, Sarah A Spinler, Michael B Streiff, Charles J Turck and 1 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of pharmacy practice, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Toni FeraProject Consultant, Greater Pittsburgh Area, PA, USA.
Allison BurnettInpatient Antithrombosis Stewardship Service, University of New Mexico Hospital, Albuquerque, NM, USA.
Jessica GrandoniDepartment of Pharmacy, Brigham and Women's Hospital, Boston, MA, USA.
Mary R MooreMass General Brigham, Boston, MA, USA.
Barbara B NussbaumASHP Research and Education Foundation, Bethesda, MD, USA.
Charles V PollackDepartment of Emergency Medicine, University of Mississippi, Jackson, MS, USA.
Anne E RoseDepartment of Pharmacy, UW Health, Madison, WI, USA.
Sarah A SpinlerDepartment of Pharmacy Practice, Binghamton University School of Pharmacy and Pharmaceutical Sciences, Binghamton, NY, USA.
Michael B StreiffDepartment of Medicine, Division of Hematology, The Johns Hopkins University, Baltimore, MD, USA.
Charles J TurckScientia Perpetuam, LLC, Greater Chicago Area, IL, USA.ORCID 0000-0002-7547-322X
John FanikosNorth American Thrombosis Forum, Brookline, MA, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Medication-use evaluations are meant to ensure that medication-use processes are consistent with prevailing standards of care, assure optimal use of therapy, and reduce the risk of medication-related problems. Reversal agents for direct oral anticoagulants are a worthy focus for medication-use evaluations for reasons of efficacy, safety, and cost. A multidisciplinary team of experts developed 2 medication-use evaluation templates illustrating the application of professional society guidelines to the appropriate use of andexanet alfa.

Indexed as

Factor XaFactor Xa InhibitorsRecombinant ProteinsAnticoagulantsBlood CoagulationHumansAnticoagulantsFactor XaFactor Xa InhibitorsPRT064445Recombinant Proteinsandexanet alfaanticoagulant reversal agentshemorrhageintracranial hemorrhagesmedication review

Identifiers

PMID39030931
PMCPMC11639411

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.